Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma.

Ther Adv Med Oncol · 2023 · PMC10495918 · PMID 37705533

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

We found that there were differences even within the Child–Pugh B subset; patients with Child–Pugh B7 showed a trend of better ORR, median PFS, and OS results compared with the Child–Pugh B8–B9 group.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.